Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers

Biomaterials

Volumn 33, Issue 30, 2012, Pages 7519-7529

  Mi, Yu ^a   Liu, Xiaoli ^a   Zhao, Jing ^a   Ding, Jun ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biodegradable copolymers; Biological therapy; Cancer nanotechnology; Herceptin ; Hyperthermia; Nanomedicine

Indexed keywords

BIODEGRADABLE COPOLYMERS; BIOLOGICAL THERAPY; CANCER NANOTECHNOLOGY; HERCEPTIN; HYPERTHERMIA;

CELL CULTURE; CHEMOTHERAPY; CONJUGATED POLYMERS; COPOLYMERS; HYPERTHERMIA THERAPY; IRON OXIDES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYETHYLENE GLYCOLS;

DISEASES;

CARBOXYL GROUP; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRON OXIDE; NANOPARTICLE; POLY(LACTIDE)DEXTRO, ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; POLYLACTIDE; POLYMER; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; ELECTRICITY; FERRIC COMPOUNDS; HUMANS; HYPERTHERMIA, INDUCED; INHIBITORY CONCENTRATION 50; MAGNETICS; NANOPARTICLES; NEOPLASMS; PHOTOELECTRON SPECTROSCOPY; POLYETHYLENE GLYCOLS; SUCCINATES; TAXOIDS; TEMPERATURE;

EID: 84865027076     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.100     Document Type: Article

References (40)

1. Feng S.S., Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003, 58:4087-4114.
2. Chan W.C.W., Kim B.Y.S., Rutka J.T. Current concepts: nanomedicine. New Engl J Med 2010, 363:2434-2443.
3. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
4. Gan C.W., Chien S., Feng S.S. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des 2010, 16:2308-2320.
5. Feng S.S. Chemotherapeutic engineering: concept, feasibility, safety and prospect-a tribute to Shu Chien's 80th birthday. Cell Mol Bioeng 2011, 4:708-716.
6. Capri G., Tarenzi E., Fulfaro F., Gianni L. The role of taxanes in the treatment of breast cancer 1995, Conference on perspectives in breast cancer Phoenix, Az, p. 68-75.
7. Bissery M.C., Nohynek G., Sanderink G.J., Lavelle F. Docetaxel (Taxotere(R)) - a review of preclinical and clinical-experience .1. preclinical experience. Anti Canc Drugs 1995, 6:339-355.
8. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff M.T., Mangatal L., Potier P. Relationships between the structure of taxol analogs and their antimitotic activity. J Med Chem 1991, 34:992-998.
9. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
10. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
11. Nahta R., Yu D.H., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280.
12. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
13. Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008, 13:515-525.
14. Mi Y., Liu Y.T., Guo Y.J., Feng S.S. Herceptin (R)-conjugated nanocarriers for targeted imaging and treatment of HER2-positive cancer. Nanomedicine-UK 2011, 6:311-312.
15. Liu Y., Li K., Liu B., Feng S.S. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010, 31:9145-9155.
16. Zhao J., Mi Y., Liu Y.T., Feng S.S. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 2012, 33:1948-1958.
17. Kumar C.S.S.R., Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliver Rev 2011, 63:789-808.
18. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
19. Gupta A.K., Naregalkar R.R., Vaidya V.D., Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2007, 2:23-39.
20. Prashant C., Dipak M., Yang C.T., Chuang K.H., Jun D., Feng S.S. Superparamagnetic iron oxide-loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials 2010, 31:5588-5597.
21. Chandrasekharan P., Maity D., Yong C.X., Chuang K.H., Ding J., Feng S.S., et al. (d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials 2011, 32:5663-5672.
22. Jego G., Hazoume A., Seigneuric R., Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2010.
23. Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002, 3:487-497.
24. Issels R. Hyperthermia combined with chemotherapy - biological rationale, clinical application, and treatment results. Onkologie 1999, 22:374-381.
25. Mohamed F., Stuart O.A., Glehen O., Urano M., Sugarbaker P.H. Docetaxel and hyperthermia: factors that modify thermal enhancement. J Surg Oncol 2004, 88:14-20.
26. Mohamed F., Marchettini P., Stuart O.A., Urano M., Sugarbaker P.H. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003, 10:463-468.
27. Richardson P.G., Mitsiades C.S., Laubach J.P., Lonial S., Chanan-Khan A.A., Anderson K.C. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Brit J Haematol 2011, 152:367-379.
28. Zhang Z.P., Yang X.L., Feng S.S. Copolymer technology for advanced nanomedicine. Nanomedicine 2011, 6:583-587.
29. Zhang Z., Huey Lee S., Feng S.S. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 2007, 28:1889-1899.
30. Mi Y., Liu Y., Feng S.S. Formulation of docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
31. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
32. Pan J., Feng S.S. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials 2009, 30:1176-1183.
33. Sun S.H., Zeng H., Robinson D.B., Raoux S., Rice P.M., Wang S.X., et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004, 126:273-279.
34. Sun B., Feng S.S. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine 2009, 4:431-445.
35. Oleson J.R. Eugene Robertson special lecture hyperthermia from the clinic to the laboratory - a hypothesis. Int J Hyperther 1995, 11:315-322.
36. Vujaskovic Z., Song C.W. Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperther 2004, 20:163-174.
37. Nabholtz J.M., Gligorov J. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmaco 2005, 6:1555-1564.
38. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
39. Zhang J.P., Dewilde A.H., Chinn P., Foreman A., Barry S., Kanne D., et al. Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia. Int J Hyperther 2011, 27:682-697.
40. Kullberg M., Mann K., Owens J.L. A two-component drug delivery system using Her-2-targeting thermosensitive liposomes. J Drug Target 2009, 17:98-107.